Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin

A growing understanding of the molecular interactions between immune effector cells and target tumor cells, coupled with refined gene therapy approaches, are giving rise to novel cancer immunotherapeutics with remarkable efficacy in the clinic against both solid and liquid tumors. To date, the most successful immunotherapies are those targeting blood-borne tumors.

Download this application note to learn how the ACEA xCELLigence system can:

• Evaluate the potency of an immunotherapy against a broad spectrum of liquid tumors
• Monitor the destruction kinetics of liquid cancers at physiologically relevant effector:target cell ratios
• Facilitate easy potency comparisons between immunotherapy treatments and dosages